People Background Check
Find People:

Rajesh A Gandhi, Age 53934 Prospect St, Westfield, NJ 07090

Get Report
Known as:
Rajesh S Gandhi Rajesh A Ghandi Rajesh A Ganehi Rajesh A Gandhu Ralesh Gandhi Rejesh Gandhi Raj Gandhi Shefali Gandhi Gandhi Rejesh Gandhi Ra
Related to:
Rajesh Gandni 65

Rajesh Gandhi Phones & Addresses

934 Prospect St, Westfield, NJ 07090 (908) 233-5050

8 Hartlander St, East Brunswick, NJ 08816

Delanco, NJ

New York, NY

Madison, WI

Stamford, CT

Bergenfield, NJ

Austin, TX

375 S End Ave APT 21S, New York, NY 10280

Show more

Mentions for Rajesh A Gandhi

Career records & work history

Medicine Doctors

Rajesh R. Gandhi

Specialties:
General Surgery, Traumatic Surgery
Work:
Texas Health Care PLLCJPS Health Network General Surgery
1500 S Main St FL 4 STE 303, Fort Worth, TX 76104
(817) 927-1171 (phone) (817) 927-1605 (fax)
Site
John Peter Smith Health Network General Surgery
1500 S Main St, Fort Worth, TX 76104
(817) 921-3431 (phone) (817) 927-1605 (fax)
Education:
Medical School
Albany Medical College
Graduated: 1992
Procedures:
Colonoscopy, Gallbladder Removal, Hemorrhoid Procedures, Hernia Repair, Laparoscopic Appendectomy, Laparoscopic Gallbladder Removal, Nephrectomy, Small Bowel Resection, Spleen Surgey, Thoracoscopy, Tracheostomy, Upper Gastrointestinal Endoscopy
Conditions:
Cholelethiasis or Cholecystitis, Gastrointestinal Hemorrhage, Inguinal Hernia, Intestinal Obstruction, Malignant Neoplasm of Colon, Overweight and Obesity, Rectal, Abdomen, Small Intestines, or Colon Cancer, Skin Cancer, Ventral Hernia
Languages:
English, Spanish
Description:
Dr. Gandhi graduated from the Albany Medical College in 1992. He works in Fort Worth, TX and 1 other location and specializes in General Surgery and Traumatic Surgery. Dr. Gandhi is affiliated with Baylor Scott & White Medical Center Waxahachie, John Peter Smith Health Network and Texas Health Harris Methodist Hospital Fort Worth.

Rajesh T. Gandhi

Specialties:
Infectious Disease
Work:
Massachusetts General Hospital Infectious Disease Inpatient Clinic
55 Fruit St, Boston, MA 02114
(617) 726-3812 (phone) (617) 726-7653 (fax)
Education:
Medical School
Harvard Medical School
Graduated: 1990
Conditions:
Candidiasis, Herpes Genitalis, Herpes Simplex, HIV Infection, Lyme Disease, Osteomyelitis
Languages:
English, Spanish
Description:
Dr. Gandhi graduated from the Harvard Medical School in 1990. He works in Boston, MA and specializes in Infectious Disease. Dr. Gandhi is affiliated with Massachusetts General Hospital.

License Records

Rajesh Gandhi

Licenses:
License #: 16109 - Expired
Issued Date: Jul 26, 1995
Renew Date: May 31, 1996
Expiration Date: May 31, 1996
Type: Certified Public Accountant

Rajesh Ramesh Gandhi

Licenses:
License #: MT041875T - Expired
Category: Medicine
Type: Graduate Medical Trainee

Rajesh Gandhi resumes & CV records

Resumes

Rajesh Gandhi Photo 38

Rajesh Gandhi

Location:
Greater New York City Area
Industry:
Accounting
Rajesh Gandhi Photo 39

Vice President And Senior Portfolio Manager

Location:
P/O Box 418210, Kansas City, MO
Industry:
Financial Services
Work:
American Century Investments
Vice President and Senior Portfolio Manager
Education:
University of Wisconsin - Madison 1988 - 1993
Bachelors, Bachelor of Science, Real Estate, Finance Homestead High School
Skills:
Banking, Valuation, Portfolio Management, Asset Managment, Relationship Management, Due Diligence, Investments, Vendor Management, Retail Banking, Team Management, Risk Management, Corporate Finance, Negotiation, Loans
Rajesh Gandhi Photo 40

Rajesh Gandhi

Rajesh Gandhi Photo 41

Rajesh Gandhi

Rajesh Gandhi Photo 42

Rajesh Gandhi

Rajesh Gandhi Photo 43

Rajesh Gandhi

Location:
United States
Rajesh Gandhi Photo 44

Rajesh Gandhi

Location:
United States
Rajesh Gandhi Photo 45

Associate Director At Bristol Meyers Squibb

Location:
Greater New York City Area
Industry:
Pharmaceuticals

Publications & IP owners

Us Patents

Bioavailable Capsule Compositions Of Amorphous Alpha-(N-Sulfonamido)Acetamide Compound

US Patent:
8252821, Aug 28, 2012
Filed:
Apr 12, 2010
Appl. No.:
12/758385
Inventors:
Sachin Chandran - Highland Park NJ, US
Rajesh Babulal Gandhi - Plainsboro NJ, US
Jaquan Kalani Levons - Ewing NJ, US
Robert Kevin Perrone - Belle Mead NJ, US
Christopher P. Price - Kentfield CA, US
Krishnaswamy Srinivas Raghavan - Cranbury NJ, US
Ismat Ullah - Cranbury NJ, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 31/4245
A61P 25/28
US Classification:
514364
Abstract:
Pharmaceutical capsule compositions containing the active compound (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide, and polyethylene glycol (PEG), Vitamin E polyethylene glycol succinate, polyvinylpryrrolidone (PVP) or copovidone (PVP-Polyvinyl acetate), with or without citric acid, are provided.

Stable Protein Formulations

US Patent:
8476239, Jul 2, 2013
Filed:
Dec 19, 2006
Appl. No.:
12/086876
Inventors:
Manisha M. Dali - Bridgewater NJ, US
Charles E. Dahlheim - Lawrenceville NJ, US
Sunita Borsadia - Plainsboro NJ, US
Vijay H. Naringrekar - Princeton NJ, US
Rajesh Babulal Gandhi - Plainsboro NJ, US
Manoj Nerurkar - Mumbai, IN
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 38/16
US Classification:
514 212
Abstract:
The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.

Stavudine Polymorphic Form 1 Process

US Patent:
2003022, Dec 4, 2003
Filed:
Oct 11, 2002
Appl. No.:
10/269358
Inventors:
Simon Bristow - West Yorkshire, GB
Philip Cocks - Hudderson, GB
Ronald Harland - Yardley PA, US
Rajesh Gandhi - Plainsboro NJ, US
International Classification:
A61K031/513
C 07D 4 5/04
US Classification:
544/310000
Abstract:
A process for the formation of Stavudine Polymorphic Form I from a mixture comprising Polymorphic Form I and at least one of Polymorphic Forms II and III is disclosed using the technique of Solution-Enhanced Dispersion by Supercritical Fluids (SEDS). A solution of the mixture in isopropyl alcohol/water is introduced into a particle formation vessel with a supercritical fluid under controlled temperature and pressure whereby the supercritical fluid substantially simultaneously disperses and extracts the solvent from the solution forming discrete particles of Stavudine Polymorphic Form I. A preferred supercritical fluid is carbon dioxide.

Process For Preparing Novel Crystalline Forms Of (2S)-1-[[(7R)-7-(3,4-Dichlorophenyl)-4,7-Dihydro-5-Methylpyrazolo[1,5]Pyrimidine-6-Yl]Carbonyl]-2-(4-Fluorophenyl)Pyrrolidine, Novel Stable Forms Produced Therein And Formulations

US Patent:
2006012, Jun 15, 2006
Filed:
Nov 21, 2005
Appl. No.:
11/283651
Inventors:
Xuebao Wang - East Brunswick NJ, US
Chiajen Lai - Kendall Park NJ, US
Nachimuthu Soundararajan - Kendall Park NJ, US
Nina Nguyen - North Brunswick NJ, US
Weiming Ying - Martinsville NJ, US
Lori Burton - Robbinsville NJ, US
Rajesh Gandhi - Plainsboro NJ, US
Krishnaswamy Raghavan - Cranbury NJ, US
Ronald West - Lawrenceville NJ, US
Yuji Zhou - Freehold NJ, US
Lin Yan - East Brunswick NJ, US
Xiaotian Yin - Plainsboro NJ, US
John DiMarco - East Brunswick NJ, US
Jack Gougoutas - Princeton NJ, US
International Classification:
A61K 31/519
C07D 487/04
US Classification:
514259300, 544281000
Abstract:
A process is provided for preparing novel crystalline forms, namely selectively and consistently preparing the H2-1 dihydrate crystalline form, the H2-2 dihydrate crystalline form, the N-3 anhydrate crystalline form and the MTBE solvate crystalline form of the IKur compound (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine. The process includes preparation of the H2-1 and H2-2 forms which are used in preparing the N-3 anhydrate form which is particularly stable and has suitable flow properties and desired particle size. Novel H2-1 dihydrate and H2-2 dihydrate forms, the N-3 anhydrate form and the MTBE solvate form of the above IKur compound, pharmaceutical compositions containing such novel forms and a method for preventing or treating arrhythmias including atrial fibrillation and IKur related conditions employing such novel forms are also provided.

Stable Oral Pharmaceutical Composition Containing Thyroid Hormone Receptor Agonists

US Patent:
2009022, Sep 3, 2009
Filed:
Mar 27, 2007
Appl. No.:
12/225631
Inventors:
Neeraj Garg - Tumba, SE
Venkatramana M. Rao - Edison NJ, US
Rajesh B. Gandhi - Plainsboro NJ, US
William N. Washburn - Titusville NJ, US
Konrad Koehler - Huddinge, SE
Johan Malm - Trangsund, SE
International Classification:
A61K 9/30
A61K 31/235
A61K 31/192
US Classification:
424475, 514532, 514568
Abstract:
Compositions are described in which certain thyroid hormone receptor-binding compounds are formulated together with either an enteric coating, an antioxidant, or both an enteric coating and an antioxidant. Such formulation acts to prevent the formation of undesired reaction products in vivo.

Stable Subcutaneous Protein Formulations And Uses Thereof

US Patent:
2013021, Aug 22, 2013
Filed:
Mar 12, 2013
Appl. No.:
13/796586
Inventors:
BRISTOL-MYERS SQUIBB COMPANY - , US
CHARLES E. DAHLHEIM - LAWRENCEVILLE NJ, US
SUNITA BORSADIA - PLAINSBORO NJ, US
VIJAY H. NARINGREKAR - PRINCETON NJ, US
RAJESH BABULAL GANDHI - PLAINSBORO NJ, US
MANOJ NERURKAR - KAIYANI NAGAR, IN
Assignee:
BRISTOL-MYERS SQUIBB COMPANY - PRINCETON NJ
International Classification:
C07K 16/28
C07K 14/705
US Classification:
4241341
Abstract:
The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.

Methods Of Using Ctla4Ig Subcutaneous Formulations

US Patent:
2020023, Jul 23, 2020
Filed:
Mar 24, 2020
Appl. No.:
16/828867
Inventors:
- Princeton NJ, US
Charles E. Dahlheim - Lawrenceville NJ, US
Sunita Borsadia - Plainsboro NJ, US
Vijay H. Naringrekar - Princeton NJ, US
Rajesh Babulal Gandhi - Plainsboro NJ, US
Manoj Nerurkar - Bellandur, IN
International Classification:
A61K 47/10
C07K 16/28
C07K 14/705
A61K 9/00
A61K 38/17
Abstract:
The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.

Stable Subcutaneous Protein Formulations And Uses Thereof

US Patent:
2018036, Dec 20, 2018
Filed:
Sep 4, 2018
Appl. No.:
16/121287
Inventors:
- Princeton NJ, US
Charles E. Dahlheim - Lawrenceville NJ, US
Sunita Borsadia - Plainsboro NJ, US
Vijay H Naringrekar - Princeton NJ, US
Rajesh Babulal Gandhi - Plainsboro NJ, US
Manoj Nerurkar - Bellandur, IN
International Classification:
A61K 47/10
A61K 9/00
C07K 16/28
A61K 38/17
C07K 14/705
Abstract:
The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.

Possible Relatives

Denish Gandhi  Darshan C Gandhi  Devendra H Gandhi  Dilip M Gandhi  Dipti Gandhi  Gita A Gandhi  Hema M Gandhi  Rajesh C Nair  Rajesh M Persaud  Rajesh Y Singh 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.